cefiderocol sulfate tosylate: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
cefiderocol sulfate tosylate: clinical details
Prescribing considerations
- Reserve for adults with aerobic Gram-negative infection and limited options, following consultation with an appropriately experienced infection specialist.
- Obtain cultures and susceptibility information where possible and reassess microbiological and clinical response.
- Provide additional cover when Gram-positive or anaerobic pathogens may contribute.
- Clinical data in highly resistant infections are limited. A trial found higher all-cause mortality with cefiderocol than best available therapy; the cause was not established, with an association observed among Acinetobacter infections.
- Account for the product's sodium content in patients requiring sodium restriction.
Contraindications and cautions
- Hypersensitivity to cefiderocol or any excipient.
- Hypersensitivity to any cephalosporin antibacterial.
- Previous severe hypersensitivity, including anaphylaxis or a severe skin reaction, to another beta-lactam antibacterial.
Monitoring
- Check renal function regularly because exposure and administration requirements depend on renal clearance.
- Monitor clinical response, cultures and susceptibility, including for overgrowth of non-susceptible organisms.
- Assess promptly for hypersensitivity, Clostridioides difficile-associated diarrhoea and neurological toxicity.
- Consider liver tests, creatinine and blood counts according to clinical circumstances.
- Urine dipsticks may give false-positive protein, ketone or occult-blood results, and Coombs tests may become positive.
Clinical pharmacology
Cefiderocol is a time-dependent siderophore cephalosporin whose pharmacodynamic index is unbound time above the organism's minimum inhibitory concentration. It uses bacterial iron transport to reach the periplasm, inhibits penicillin-binding proteins and is eliminated mainly unchanged by the kidneys; haemodialysis removes a substantial proportion.
Formulation and product differences
- Single-use powder for concentrate for solution for infusion.
- Requires aseptic reconstitution followed by dilution in compatible sodium chloride or glucose infusion fluid; it is not suitable for direct injection.
- The vial contains sodium and should be refrigerated and protected from light before preparation.
cefiderocol sulfate tosylate interactions
Clinically important metabolic interactions are not expected, but administration compatibility and diarrhoea management require attention.
CYP enzyme or transporter substrates, inhibitors and inducers
Available studies indicate that clinically significant pharmacokinetic interactions are not anticipated.
Midazolam, furosemide, metformin and rosuvastatin
Clinical interaction studies found no changes considered clinically meaningful.
Other intravenous medicines
Do not mix them with cefiderocol in the same syringe or infusion solution; flush shared intravenous lines appropriately.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.